SETD7/KMT7

SETD7 (KMT7) is a SET domain-containing lysine methyltransferase that primarily catalyzes histone H3 lysine 4 monomethylation (H3K4me1), an epigenetic mark associated with transcriptional activation and enhancer function^[1][2]. Mechanistically, SETD7 regulates gene expression through both histone and non-histone substrate methylation, extending its influence beyond chromatin remodeling to the control of protein stability, subcellular localization, and protein-protein interactions^[3][4]. In addition to histone H3, SETD7 methylates multiple regulatory proteins, including p53, TAF10, and cGAS, thereby linking lysine methylation to transcriptional regulation, stress responses, and innate immune signaling^[2][3]. Consequently, SETD7 participates in diverse biological processes, including cell differentiation, cell-cycle control, apoptosis, epithelial-mesenchymal transition, and DNA damage responses^[4]. In disease settings, extensive evidence implicates SETD7 in cancer-associated pathways, although its biological effects are highly dependent on cellular context and substrate availability^[4][5]. For example, SETD7-mediated methylation can stabilize tumor-suppressive proteins such as p53 or promote degradation of oncogenic KRAS, thereby attenuating RAS/MEK/ERK signaling in non-small cell lung cancer models^[3][5]. Compared with other lysine methyltransferases that predominantly target histones, SETD7 is distinguished by its broad repertoire of non-histone substrates and its ability to directly modulate signaling networks through substrate-specific methylation events^[2][3]. For experimental applications, SETD7 is frequently investigated as a regulator of epigenetic signaling and protein methylation, making it a useful target for mechanistic studies of transcriptional control, cancer biology, and cellular stress responses^[4].